Selective CDK4 inhibition holds promise for breast cancer

Abstract

Although CDK4/6 inhibitors have revolutionized the management of patients with locally advanced/metastatic HR⁺HER2⁻ breast cancer, hematological side effects, notably neutropenia, have been challenging to circumvent. A highly selective CDK4 inhibitor has recently been shown to cause limited hematological toxicity in preclinical breast cancer models, hence enabling dose escalation in support of superior tumor control.